The Role of Interferon-γ in the Treatment of Visceral and Diffuse Cutaneous Leishmaniasis

Journal of Infectious Diseases

Volumn 167, Issue , 1993, Pages S13-S17

  Badaró, Roberto ^a,b   Johnson, Warren D ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIMONY DERIVATIVE; GAMMA INTERFERON; MEGLUMINE ANTIMONATE; PENTAMIDINE; STIBOGLUCONATE SODIUM;

CLINICAL FEATURE; CLINICAL SKIN REACTION; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; HUMAN; IMMUNE DEFICIENCY; PRIORITY JOURNAL; SKIN LEISHMANIASIS; THERAPY RESISTANCE; VISCERAL LEISHMANIASIS;

ANTIMONY; HUMAN; INTERFERON TYPE II; LEISHMANIASIS, DIFFUSE CUTANEOUS; LEISHMANIASIS, VISCERAL; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027535826     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/167.Supplement_1.S13     Document Type: Article

References (24)

1. Fiorentino OF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV: Th2 clones secrete a factor that inhibits cytokine production by Th I clones. J Exp Med 1989; 170:2081-95.
2. Mosmann TR, Coffman RL. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv Immunol 1989;46: 111-47.
3. Mosmann TR, Coffman RL. Two types of mouse helper T-cell clones. Implication for immune regulation. Immunol Today 1987;8:223-7.
4. Liew FY. Functional heterogeneity of CD4+ T cells in leishmaniasis. Immunol Today 1989;10:40-5.
5. Coffman RL. Varkila R, Scott P, Chatelain R. Role ofcytokines in the. differentiation of CD4+ T cell subsets in vivo. Immunol Rev 1991;123: 189-207.
6. Belosevic M, Finbloom OS, Van Der Meide PH, et al. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major. J Immunol 1989;143:266-74.
7. Coffman RL, Chatelain R, Leal LMC, Varkila K. Leishmania major infection in mice: a model system for the study ofCD4+ T-cell subsets differentiation. Res Immunol 1991;142:36-40.
8. Marsden PD. Mucosal leishmaniasis ("espundia" Escornel, 1911). Trans R Soc Trop Med Hyg 1986;80:859-76.
9. Carvalho EM, Badaro R, Reed SG, et al. Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis. J Clin Invest 1985;76:2066-9.
10. Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis 1986; 154:1003-11.
11. Bryceson ADM. Diffuse cutaneous leishmaniasis in Ethiopia. I: the clinical and histological features of the disease. Trans R Soc Trop Med Hyg 1969;63:708-37.
12. Andrade TM, Teixeira R, Andrade JAF, et al. Hipersensibilidade de tipo retardado na leishmaniose visceral. Rev Inst Med Trop Sao Paulo 1982;24:298-302.
13. Carvalho EM, Bacellar O, Barral A, et al. Antigen-specific immune suppression in visceral leishmaniasis is cell mediated. J Clin Invest 1989;83:860-4.
14. Barral A, Carvalho EM, Badaro R, Barral-Netto M. Suppression of lymphocyte proliferative response by sera from patients with American visceral leishmaniasis. Am J Trop Med Hyg 1986;35:735-42.
15. Murray HW, Rubin BY, Rothermel CD. Killing of intracellular Leishmania donovani by Iymphokine-stimulated human mononuclear phagocytes: evidence that interferon gamma is the activating Iymphokine. J Clin Invest 1983;72: 1506-10.
16. Nathan CF, Kaplan G, Levis WR, et al. Local and systemic effects of intradermal recombinant interferon gamma in patients with lepromatous leprosy. N Engl J Med 1986;315:6-15.
17. Murray HW, Berman JD, Wright SO. Immunochemotherapy for intracellular Leishmania donovani infection: ')' interferon plus pentavalent antimony. J Infect Dis 1988;157:973-8.
18. Crawford GO, Wyler OJ, Dinarello CA. Parasite-monocyte interactions in human leishmaniasis: production of inter leukin I in vitro. J Infect Dis 1985; 152:315-22.
19. Reiner NE, Ng W, McMaster WR. Parasite-accessory cell interactions in murine leishmaniasis. II: Leishmania donovani suppresses macrophage expression of class I and class II major histocompatibility complex gene products. J Immunol 1987; 138:1926-32.
20. Reiner NE, Malemud CJ. Arachidonic acid metabolism by murine peritoneal macrophages infected with Leishmania donovani: in vitro evidence for parasite-induced alterations in cyclooxygenase and lipoxygenase pathways. J ImmunoI1985;134:556-63.
21. Reiner NE, Ng W, Ma T, McMaster WR. Kinetics of gamma interferon binding and induction of major histocompatibility complex class II mRNA in leishmania-infected macrophages. Proc Natl Acad Sci USA 1988;85:4330-4.
22. Ezekowitz RAB, Dinauer M, Jaffe HS, et al. Partial correction of the phagocyte defect in patients with X-linked chronic granulomatous disease by subcutaneous interferon gamma. N Engl J Med 1988;319: 146-51.
23. Badaro R, Falcoff E, Badaro FS, et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 1990;322: 16-21.
24. Chulay JD, Brycesson AD. Quantitation of amastigotes of Leishmania donovani in smears of splenic aspirates from patients with visceral leishmaniasis. Am J Trop Med Hyg 1983;32:475-9.